Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2023-09-27 M&A Activity
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
[기재정정]수시공시의무관련사항(공정공시)(아일리아 바이오시밀러(SCD411) Binding Term Sheet 체결)
M&A Activity Classification · 100% confidence The document is a regulatory filing from Samchundang Pharm regarding a 'Binding Term Sheet' for a biosimilar product. It is explicitly labeled as a 'Correction Report' (정정신고) for a previous disclosure, updating the expected date for the final contract signing due to delays in due diligence. Since this is a regulatory disclosure of a material business event (contract update) filed with the Korean financial authorities, it falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually implies corporate mergers/acquisitions) or specific financial reports.
2023-09-27 Korean
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Samchundang Pharm regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. This involves the issuance of new shares resulting from the conversion of debt into equity, which directly impacts the company's capital structure and share count. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2023-08-31 Korean
투자판단관련주요경영사항(황반변성치료제(아일리아/주성분 : Aflibercept) 바이오시밀러 SCD411(Vial&PFS)의 캐나다 독점판매권 및 공급계약 체결)
M&A Activity Classification · 100% confidence The document is a formal regulatory filing from Samchundang Pharm regarding a major business decision: the signing of an exclusive supply and sales agreement for a biosimilar drug (SCD411) in Canada. It details the contract terms, milestones, and financial implications. Since this is a specific corporate announcement regarding a material business contract that does not fit into categories like M&A or share issues, it is classified as a general regulatory filing (RNS).
2023-08-23 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Samchundang Pharm Co., Ltd. for the period of January 1, 2023, to June 30, 2023. It contains detailed financial information, business operations, production capacity, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-14 Korean
풍문또는보도에대한해명(미확정)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system, specifically a 'Clarification of Rumors or Reports' (풍문 또는 보도에 대한 해명). This type of filing is a standard regulatory requirement in the Korean market when a company needs to address media speculation. Since it does not fit into specific categories like M&A, financial reports, or governance, it falls under the 'Regulatory Filings' (RNS) category as the designated fallback for miscellaneous regulatory announcements.
2023-07-28 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the change in shareholding percentage by a major investor (Korea Securities Finance Corp) in Samchundang Pharm. This type of filing is categorized as a Major Shareholding Notification (MRQ) as it tracks significant ownership thresholds.
2023-07-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.